EGAPP|Recommendations|CVD

EGAPP|Recommendations|CVD

EGAPP Working Group Recommendation

Use of Genomic Profiling to Assess Risk for Cardiovascular Disease (CVD) and Identify Individualized Prevention Strategies

Cardiogenomic profiles (or “heart health” profiles) are a type of genetic test.  These tests attempt to predict risk for cardiovascular disease, and look for genetic variants that may be associated with an increased risk of disease. These tests are being marketed to physicians and the general public as a way to find out a person’s risk of developing cardiovascular disease. Some of these tests can be ordered online and without the involvement of a physician.

EGAPP Recommendation Statement: The Evaluation of Genomic Applications in Practice and Prevention Working Group (EWG) found insufficient evidence to recommend testing for the 9p21 genetic variant or 57 other variants in 28 genes (listed in Table 1 of article) to assess risk for cardiovascular disease (CVD) in the general population, specifically heart disease and stroke. The EWG found that the magnitude of net health benefit from use of any of these tests alone or in combination is negligible. The EWG discourages clinical use unless further evidence supports improved clinical outcomes. Based on the available evidence, the overall certainty of net health benefit is deemed “Low.”

EGAPP Recommendation (December 2010)
Evidence Report  (December 2010)
Additional Evidence Article (February 2010)
CDC Summary of EGAPP Recommendation (October 2011)